(UroToday.com) In the Guideline Session II: Prostate Cancer: cN+ in newly diagnosed patients during the 2021 European Association of Urology meeting, Dr. Guillaume Ploussard, armed with more data, argues against the need for more than ADT as systemic therapy for cN+ prostate cancer. He also provides the guideline point of view on this topic.